zolbetuximab
astellas
[]
i m still stuck on the 18.2 mo os in the spotlight trial testing the efficacy of a claudin 18.2 inhibitor. something to think about when a biomarker is named. #gi23
MOM. GI Onc @nyphospital @meyercancer @weillcornell. Founder @mmfightscrc @letswinpc @oceansblessings. @JAJForg @curepolg boards. cycleuptocancer on @onepeloton